Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Research context
Nymox Pharmaceutical Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Nymox Pharmaceutical Corporation is currently in a long term downtrend where the price is trading 33.1% below its 200 day moving average.
From a valuation standpoint, the stock is 2457.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 34253.9.
Nymox Pharmaceutical Corporation's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 24.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 6.5% to $-2M since the same quarter in the previous year.
Based on the above factors, Nymox Pharmaceutical Corporation gets an overall score of 2/5.